Mark Pastreich - Repro Med Director

Director

Mr. Mark L. Pastreich is Director of ReproMed Systems, Inc. He is a businessman, and a longtime real estate investor and broker for the past 60 years. He has served on numerous forprofit and notforprofit boards. Among his other various real estate holdings, he was a partner in Casper Creek LLC for past 18 years, which owns the building leased by the Company. Mr. Pastreich has a wealth of business acumen and experience. since 2011.
Age 87
Tenure 13 years
Phone845-469-2042
Webhttp://www.rmsmedicalproducts.com

Repro Med Management Efficiency

The company has return on total asset (ROA) of 10.67 % which means that it generated a profit of $10.67 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on stockholder's equity (ROE) of 0.27 %, meaning that it created $0.27 on every $100 dollars invested by stockholders. Repro Med's management efficiency ratios could be used to measure how well Repro Med manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 444.08 K in liabilities with Debt to Equity (D/E) ratio of 4.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Repro Med Systems has a current ratio of 5.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Repro Med until it has trouble settling it off, either with new capital or with free cash flow. So, Repro Med's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Repro Med Systems sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Repro to invest in growth at high rates of return. When we think about Repro Med's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Patricia McGinnisBrp Group
69
Craig KushnerAKITA Drilling
N/A
E PedersonNational Western Life
70
Douglas HultquistUnited Fire Group
58
Mahendra GuptaBrp Group
61
Loraine CharltonAKITA Drilling
60
Julie SchneeklothUnited Fire Group
N/A
Debra PerryAssurant
69
Krystyna HoegSun Life Financial
64
Brenda ClancyUnited Fire Group
63
Kyle SkogmanUnited Fire Group
67
Russell MoodyNational Western Life
52
Michael WilkinsQBE Insurance Group
N/A
George MilliganUnited Fire Group
61
Charles KochAssurant
72
John ClappisonSun Life Financial
68
Arthur EastlyAKITA Drilling
78
Nancy SouthernAKITA Drilling
60
Greig WoodringSun Life Financial
N/A
Brenda FreemanBrp Group
53
Lee CappsBrp Group
69
Repro Med Systems, Inc., doing business as RMS Medical Products, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York. REPRO MEDSYSTEMS operates under Medical Instruments Supplies classification in USA and is traded on BATS Exchange. It employs 75 people. Repro Med Systems [REPR] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Repro Med Systems Leadership Team

Elected by the shareholders, the Repro Med's board of directors comprises two types of representatives: Repro Med inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Repro. The board's role is to monitor Repro Med's management team and ensure that shareholders' interests are well served. Repro Med's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Repro Med's outside directors are responsible for providing unbiased perspectives on the board's policies.
Karen Fisher, CFO and Treasurer
Robert Allen, Director
Andrew Sealfon, Co-Founder, Chairman, CEO and President and Head of RandD
David Anderson, Director
Donald Pettigrew, President and Chief Commercial Officer
Manuel Marques, COO
Fred Ma, Principal Executive Officer
Mark Pastreich, Director
Daniel Goldberger, Independent Director
Cyril Narishkin, Interim COO and Additional Director
John Fletcher, Independent Director
Paul Baker, Director
James Beck, Director
Brad Sealfon, Marketing Manager and Director
Eric Bauer, COO
Arthur Radin, Director
Joseph Manko, Additional Director

Repro Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Repro Med a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Repro Med in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Repro Med's short interest history, or implied volatility extrapolated from Repro Med options trading.

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Other Consideration for investing in Repro OTC Stock

If you are still planning to invest in Repro Med Systems check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Repro Med's history and understand the potential risks before investing.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Transaction History
View history of all your transactions and understand their impact on performance
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.